ENTERA BIO LTD. Accumulated Other Comprehensive Income
ENTERA BIO LTD. (ENTX) had Accumulated Other Comprehensive Income of $41.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-07
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $41.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $41.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $41.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $41.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $41.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $41.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $41.00K 10-Q · filed 2026-08-07 |
| 2025-09-30 | $41.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $41.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $41.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $41.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $41.00K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $41.00K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $41.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $41.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $41.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $41.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $41.00K 10-Q · filed 2023-05-05 |
| 2022-12-31 | $41.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $41.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $41.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $41.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $41.00K 10-K · filed 2023-03-31 |
| 2020-12-31 | $41.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |